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Abstract
Background: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension
study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate
receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome
(FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the
narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale.
Methods: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100 mg BID) or placebo
over 12 weeks. In the extension, patients received 100 mg BID mavoglurant (or the highest tolerated dose) for up
to 32 months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale.
Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very
much worse) were provided a standard narrative template to collect further information about the changes
observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening
to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized
using the Cochran–Mantel–Haenszel test.
Results: A total of 134 and 103 patients had reached 2 weeks or more of core and extension study treatment,
respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2
were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater
treatment response in patients receiving mavoglurant compared with placebo in any specific improvement
domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported
categories of improvement were behavior and mood (79.3 and 76.6 % in core and extension studies, respectively),
engagement (75.9 and 78.7 %), and communication (69.0 and 61.7 %).
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Conclusions: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although
this method did not show benefit of drug over placebo, narratives from investigators were mostly based on
parental report and thus do not represent a completely objective alternative assessment.
Trial registration: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers
NCT01357239 and NCT01433354.
Keywords: Mavoglurant, AFQ056, Fragile X syndrome, Clinical Global Impression-Improvement, CGI-I
Background
Fragile X syndrome (FXS) is an X-linked genetic condi-
tion associated with an expansion of the trinucleotide
CGG repeat within the 5’ untranslated region of the fra-
gile X mental retardation 1 (FMR1) gene [1]. It is the
most common inherited cause of intellectual disability
with a prevalence of 1 in 4000–7000 for males and 1 in
8000–11,000 for females [2, 3]. Individuals with a full
mutation frequently present with mild-to-moderate in-
tellectual and learning disabilities.
FXS is associated with a heterogeneous clinical pheno-
type, which is characterized by cognitive and behavioral
impairments, as well as physical features such as macro-
orchidism (in males), macrocephaly, large prominent
ears, hypotonia, long face, flat feet, soft skin, high-
arched palate, and hyperextensible joints [4–6]. Female
individuals with FXS tend to present with less severe
physical and behavioral characteristics than males. Com-
mon behavioral symptom categories include anxiety,
hyperactivity, aggression, attention deficits, impulsivity,
and mood lability, with motor stereotypies, social avoid-
ance, and poor eye contact also often present [5]. In
addition, features of autistic spectrum disorder are found
in a high proportion of patients with FXS [4–6].
The full mutation leads to methylation of the sur-
rounding nucleotide sequences and hence inhibition of
FMR1 gene transcription [7–9]. The fragile X mental re-
tardation protein (FMRP, the gene product of FMR1) is
an RNA-binding protein involved in the transport [10]
and translational regulation of various dendritic mRNAs
at synapses [11]. Absence of FMRP results in defects in
synaptic plasticity and enhanced long-term depression
(LTD) [12, 13]. On the basis of findings from several
studies, it has been proposed that dysregulation of the
metabotropic glutamate receptor subtypes 1 and 5
(mGluR1/5) pathways, involved in LTD and synaptic
plasticity, contributes to many of the symptoms of FXS
[13]. A number of clinical trials have assessed the thera-
peutic potential of strategies targeting the mGluR5 path-
ways. The agents investigated include fenobam, RG7090
(R04917523), and mavoglurant (AFQ056) [4, 14, 15].
Mavoglurant, a selective mGluR5 antagonist, has been
evaluated for the treatment of behavioral symptoms in pa-
tients with FXS. In a phase II, randomized, double-blind,
placebo-controlled, two-treatment, two-period, crossover
study of 30 male patients with FXS aged 18–35 years, no
significant treatment differences were found between
mavoglurant and placebo on the primary outcome meas-
ure, the Aberrant Behavior Checklist-Community Edition
(ABC-C) total score, at day 19 or 20 [15]. Furthermore, no
significant effects of mavoglurant on other secondary out-
come measures, including the Clinical Global Impression
(CGI) scale, Visual Analog Scale (VAS) of behavior, Social
Responsiveness Scale-Adult Research Version (SRS-A), and
Vineland Adaptive Behavior Scale (VABS), were reported.
However, an exploratory analysis suggested improvement
in the ABC-C total score (p < 0.001), ABC-C stereotypic
behavior, hyperactivity, inappropriate speech subscales
(p < 0.05), CGI-Improvement (CGI-I; p < 0.001), Repetitive
Behavior Scale-Revised (RBS-R), SRS-A, and VAS (all p <
0.05) in a subpopulation of fully methylated males.
Subsequent mavoglurant trials have been completed in
adult (aged 18–45 years; NCT01253629) and adolescent
(aged 12–17 years; NCT01357239) patients with FXS.
These studies were 12-week, phase II, randomized,
double-blind, placebo-controlled, parallel-group studies
and have been followed up with long-term, open-label
extension studies in adults (NCT01348087) and adoles-
cents (NCT01433354). In the double-blind studies, par-
ticipants were divided into two strata depending on the
extent of methylation of their FMR1 gene. Multiple be-
havioral outcome measures were implemented across
these studies; however, mavoglurant did not demon-
strate improvement in behaviors with respect to pla-
cebo on either primary or secondary end points (ABC-C
using the FXS specific algorithm (ABC-CFX), CGI-I, RBS-
R, and SRS).
The broad spectrum of phenotypes in FXS makes find-
ing the optimal outcome measures a major challenge. In
order to capture a range of potential changes across a
number of cognitive and behavioral domains in FXS, tri-
als of pharmaceutical interventions have incorporated
multiple end points, including ABC-C and CGI [16].
With the exception of ABC-C, for which a factor ana-
lysis specific to FXS has been performed and subscales
created on the basis of the FXS factors [17], these out-
come measures are not specific to FXS and are used
across a range of central nervous system conditions.
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Clinical trials involving patients with FXS regularly use
the CGI scales as secondary end points in the assess-
ment of treatment response. CGI is a clinician-rated,
interview-based assessment that takes into account all
available information, including symptoms, behavior,
functionality, patient history, and reports from caregivers
and other sources [18]. It comprises three components:
severity (CGI-S), global improvement (CGI-I), and effi-
cacy (CGI-E) [19]. CGI-S and CGI-I are the most com-
monly used scales in clinical trials and both are scored
on a similar seven-point scale to acquire an overall assess-
ment of a patient’s condition. The CGI-S rates illness sever-
ity at the time of assessment (1 = normal, not at all ill; 2 =
borderline, mentally ill; 3 = mildly ill; 4 = moderately ill; 5 =
markedly ill; 6 = severely ill; and 7 = among the most ex-
tremely ill patients), whereas the CGI-I rates change from
baseline or from the beginning of treatment (1 = very much
improved; 2 = much improved; 3 = minimally im-
proved; 4 = no change; 5 = minimally worse; 6 = much
worse; and 7 = very much worse).
These scales were also used as the primary outcome
measure in a randomized, double-blind, placebo-controlled
trial of minocycline in children and adolescents with
FXS [20], in which a marginal but statistically significant
(p = 0.0173); improvement in the CGI-I was reported with
minocycline compared with placebo. However, there are
no standardized scoring anchors or interview guidelines
for this instrument, and consequently, the CGI-I assess-
ment is vulnerable to inter-rater variability and poor reli-
ability [21, 22]. Furthermore, although the CGI has
previously been adapted for bipolar disorder [23], schizo-
phrenia [24], Alzheimer’s disease [25], and depression
[26], to date, a version has not been developed specifically
for patients with FXS.
The analyses of the overall symptoms in adolescent pa-
tients with FXS from a 12-week, phase II, randomized,
double-blind, placebo-controlled study (NCT01357239)
using the narratives associated with the clinician-rated CGI-
I scale are presented. Analysis of the CGI-I narratives from
a follow-on open-label extension study (NCT01433354) in
adolescents with FXS has also been included in order to de-
scribe the reports in the long-term study and to see if the
effects become diminished over time, as might be expected
if there is a placebo effect.
This analysis was prompted by anecdotal reports re-
garding clinical improvement received from investigators
during the double-blind treatment, relating to symptom
categories not captured by the scales used in the study.
The intention of this analysis was to investigate the ef-
fect of mavoglurant treatment versus placebo in categor-
ies generated from analysis of the CGI-I narratives:
anxiety, behavior and mood, communication, cognitive/
academic, engagement, and functional skills, in adoles-
cent patients with FXS who reached a CGI-I score of 1,
2, 6, or 7 (i.e., patients who were considered much or




This was a prospective analysis of change in the overall
symptoms of FXS from a multicenter, phase II, random-
ized, placebo-controlled, double-blind, parallel-group
study (NCT01357239) with an open-label extension
(NCT01433354) in adolescent patients with FXS. The
primary results of the double-blind study have been de-
scribed by Berry-Kravis et al. and the open-label study
will also be reported separately.
In the core double-blind study, a protocol amendment
was implemented during randomization after approxi-
mately 70 patients had been randomized. After assess-
ment of eligibility and a 4-week, single-blind, placebo
run-in period, under the original protocol, patients were
randomized in a ratio of 1:1:1:1 to one of four treatment
arms to receive mavoglurant 25 mg BID (one capsule of
25 mg and one capsule of placebo per intake), 50 mg
BID (two capsules of 25 mg per intake), or 100 mg BID
(one capsule of 100 mg and one capsule of placebo per
intake), or placebo (two capsules of placebo per intake)
over a 12-week, double-blind period. Following the
protocol amendment, newly enrolled patients were ran-
domized in a ratio of 1:1 to one of two treatment arms
to receive mavoglurant 100 mg BID (one capsule of
100 mg and one capsule of placebo per intake) or pla-
cebo BID (two capsules of placebo per intake). Patients
randomized before the protocol amendment continued
on their assigned dose until the end of the double-blind
period. The study population was stratified by gender,
methylation status, and region during randomization.
This study was initiated in May 2011 and completed in
January 2014.
The extension was an open-label, flexible-dose, long-term
safety study in adolescent patients with FXS who had par-
ticipated in previous mavoglurant studies. Patients received
a starting dose of mavoglurant 25 mg BID, to maintain
blinding of the study in which the patients had previously
participated, and were incrementally up-titrated to a max-
imum dose of 100 mg BID or the highest tolerated dose
(25, 50, or 75 mg BID). Patients received treatment for up
to 32 months but discontinued the treatment when the
study was terminated early based on the results of the 12-
week double-blind studies in adults (NCT01253629) and
adolescents (NCT01357239) which failed to demonstrate
efficacy of mavoglurant in the target population and the
sponsor’s decision to terminate the program.
The study protocols were reviewed by the Institutional
Review Board for each center. The studies were conducted
according to the ethical principles of the Declaration of
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Helsinki. Written informed consent was obtained from
each patient’s legal guardian before any assessment was
performed.
Participants
The patients eligible to participate in the core study
were adolescent male or female patients aged 12–
17 years of age with a diagnosis of FXS confirmed by
genetic testing results (>200 CGG repeats). Patients were
also required to have a CGI-S score of ≥4 (moderately
ill), a score of >20 on the ABC-C total scale, and an
intelligence quotient of <70 as measured by the Leiter
International Performance Scale-Revised. Inclusion in
the open-label extension study required participation in
previous mavoglurant studies that had included adoles-
cent patients with FXS up to 18 years of age, provided
they were at least 12 years of age at the time of enroll-
ment into the extension study. Exclusion criteria are pre-
sented in detail in the core study paper (Berry-Kravis et
al 2015) [27]. In addition, patients were not eligible for
enrollment into the extension study if they had discon-
tinued from another mavoglurant study which included
adolescent patients with FXS because of safety reasons.
Analysis
CGI-I assessment and narratives
In both the core double-blind and open-label extension
studies, global improvement, as a measure of treatment
response, was assessed using the CGI-I scale [19]. The
CGI-I assessments were carried out by the same rater
across both the studies, whenever possible. The CGI-I
score ranges from 1 to 7 (with 1 being “very much im-
proved,” 4 being “no change,” and 7 being “very much
worse”). The scoring was performed at weeks 2, 4, 8,
and 12 in the core double-blind phase and at weeks 4,
12, and every 3 months thereafter in the open-label ex-
tension study.
Investigators who assigned patients a CGI-I score of 1
(very much improved), 2 (much improved), 6 (much
worse), or 7 (very much worse) at any time during the
studies were provided with a standard narrative template
in which to describe further the changes observed in
these patients. The CGI narratives were requested by a
cutoff date on October 4, 2013. Narratives based on a
score of 1 or 2 were considered trial responder narra-
tives, whereas scores of 6 or 7 were considered trial
worsening narratives. Patients receiving a score of 1 or 2
were subsequently referred to as “responders.”
A combination of inductive and deductive qualitative
analysis was used to develop the coding scheme. Three
Ph.D.-level experts in FXS independently reviewed re-
sponses on 10 randomly selected CGI narratives (five
from each study) and identified all of the improved
symptoms noted. These symptoms were then assigned
to several broad categories for coding based on what is
known about the FXS phenotype as well as on the nature
of the written comments. If the narratives included any
errors or discrepancies, they were not coded. Six broad
categories (anxiety, behavior and mood, communication,
cognitive/academic, engagement, and functional skills)
were identified, comprising 14 subcategories of symptom
improvement. The experts developed brief definitions for
each category and agreed on the general criteria by which
each would be assigned (see Table 1). Once the categories
were identified, the coders independently reviewed all of
the narratives and assigned each reported symptom to a
category. Any disagreements in category assignment were
discussed until a consensus was reached. The raters were
blind to whether the narratives rated were from patients
in the treatment group or the placebo group.
Table 1 Categories of improvement or worsening
1 Anxiety: any reference to reduction of anxiety, including OCD.
2. Behavior and mood: any reference to improvement in externalizing
behaviors, including following directions, reduction in aggression, and
complying with requests
a. Compliance—e.g., following direction, complying with requests
b. Transitions—e.g., willingness to change activities, ease of transitions
c. Externalizing behavior—e.g., aggression, SIB, destruction of
property, temper tantrums
d. Mood—e.g., reference to changes in mood or irritability, listlessness
3. Communication: any reference to improvement in ability to
communicate
a. Articulation—reference to intelligibility or speech production
b. Language—reference to ability to communication, word use,
spontaneous use of speech (without a clear reference to social
engagement/interactions)
4. Cognitive/academic: any reference to improvements in cognitive or
academic skills
a. Cognitive—e.g., better scores on IQ test, ability to follow complex
directions, increased cognition
b. Attention/memory/concentration—e.g., better focus, able to listen
longer
c. Academic—e.g., better math skills, increased reading, better writing
5. Engagement: any reference to improvement in engagement with
others and/or the environment
a. Social interactions—e.g., social interactions, social communication,
engagement with others, willingness to engage
b. Engagement with environment—e.g., increased interests, engaging
with activities
6. Functional skills: any reference to improvements in daily activities
including self-care, independence with functional activities
a. Self-help/daily living skills—e.g., getting dressed, feeding self,
toileting etc.
b. Independence/autonomy—e.g., improved work/job skills, more
independence in household activities
IQ intelligence quotient, OCD obsessive compulsive disorder,
SIB self-injurious behavior
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Statistical analysis
Any potential treatment effect was investigated using the
following procedure: the number of patients expected to
improve in a specific category was calculated under the
assumption that each patient had the same chance to im-
prove in that category (i.e., mavoglurant treatment would
not make a difference). A difference between the observed
and expected numbers of responders may indicate an ef-
fect of mavoglurant on a specific category. The strength of
a potential effect was characterized using the Cochran–
Mantel–Haenszel test to investigate trends according to
the dose or a general association with treatment.
Results
By the cutoff date, a total of 134 and 103 patients had
reached 2 weeks (visit 4) or more of double-blind and
open-label treatment, respectively. In the core double-
blind study, 34 CGI-I scores of 1 or 2 were reported in
29 patients (i.e., 29 patients scored 1 or 2 at least once
during the study up to the cutoff date). One patient had
a CGI-I score of 6. There were no reports of patients
with a CGI-I score of 7. All 35 narratives were received.
There were 54 occurrences of CGI-I scores of 1 or 2 in
47 patients in the long-term extension study of which 52
narratives were received. One patient had a CGI-I score
of 7 but this trial worsening narrative was not received.
After duplicates/errors were removed, 29 and 47 narra-
tives from the double-blind and open-label studies, re-
spectively, were used for coding.
Major categories and subcategorization
The distribution patterns of improvements reported
across the subcategories were comparable between the
core and long-term extension studies (Fig. 1). The most
commonly reported subcategories in both the studies
were social interaction, language, and externalizing.
These results are presented as percentage of individuals
(not subcategories) as one patient could improve in
more than one subcategory.
Following consolidation of the subcategories into six
broad categories, the reported improvements showed a
similar distribution pattern in the blinded core and
open-label extension studies. The results are based on
the counts of individual patients (or number of re-
sponders) rather than the counts of CGI-I responses.
The most frequently reported improvement categories
were behavior and mood (79.3 %), engagement (75.9 %),
and communication (69.0 %) in the core study (Fig. 2).
In the long-term study, patients exhibited similar im-
provements in behavior and mood (76.6 %) and engage-
ment (78.7 %) (Fig. 2).
In general, the percentage of patients improving was
marginally lower in the long-term study, with the largest
difference observed in anxiety (58.6 and 42.6 % in the core
and long-term extension studies, respectively). However,
the proportion of patients improving in the functional
skills (40.4 vs 31.0 %) and cognitive/academic (61.7 vs
37.9 %) categories was greater (Fig. 2) in the long-term ex-
tension study compared with the core study.
Distribution of responders in the double-blind core study
according to treatment
After the unblinding of the core study, responders
(patients receiving a score of 1 or 2) were analyzed ac-
cording to their treatment group. This statistical analysis
was conducted with 28 patients (as one patient of the 29
did not receive treatment). The CGI-I responders were
similarly distributed across treatment arms (Table 2).
Fig. 1 Percentage reported improvement across all subcategories
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Patients treated with mavoglurant did not show a higher
prevalence of reported improvements than those treated
with placebo. The response rate in each treatment group
was also similar when the analysis was repeated for the
six broad categories. Treatment with mavoglurant did
not lead to a better outcome in any of these categories
(Table 3). Worsening was reported in one patient on pla-
cebo with the following narratives: more aggression,
noncompliant, more cursing at school, much harder to
get out of bed, and lying on the ground at school.
Discussion
Here, the qualitative assessment of change in overall
symptom categories in adolescent patients with FXS,
based on the narratives linked to the clinician-rated
CGI-I scores, in a double-blind therapeutic study of
mavoglurant and an open-label extension study is re-
ported. Multiple anecdotes were received from the in-
vestigators during the double-blind treatment phase
relating significant improvements in patients. Many of
these anecdotes referred to categories such as language,
cognition, and social interaction; categories that were
not captured by the ABC-C, SRS, RBS, or CGI assess-
ments used in the study. Consequently, a systematic col-
lection of narratives for the patients rated by their
clinician as “very much improved” or “much improved”
(CGI-I score of 1 or 2) and “much worse” or “very much
worse” (CGI-I score of 6 or 7) was instigated to further
clarify the nature of these anecdotally reported improve-
ments in the core double-blind and open-label extension
studies.
In all, 29 of 134 patients in the core study and 47 out
of 103 patients in the extension study scored 1, 2, 6, or 7
at least once. Only one patient from each study was
rated as worsening (CGI-I score of 6 or 7). A key objective
of this analysis was to better understand any potential effi-
cacy of mavoglurant in patients with FXS by the analysis
of symptom categories described in the clinician-provided
narratives among patients with high levels of observed im-
provement. A further objective was to identify other cat-
egories of improvement with greater relevance in FXS
than those currently included in the various outcome
measurement scales.
Following treatment unblinding, responder distribu-
tion was assessed across the core study treatment arms.
Individuals in the active treatment group did not per-
form better on any of the outcome categories compared
with placebo. Overall, the CGI-I narrative analysis did
not indicate an effect of mavoglurant on the number of
responders or responses versus placebo. However, inter-
estingly, cognitive/academic and functional gains were
reported more frequently during the long-term exten-
sion study than during the core study. Benefits in these
areas would be more expected to emerge with extended
Fig. 2 Percentage of patients who reported improvement in broad categories
Table 2 Distribution of responders across the treatment arms (double-blind core study)
Placebo Mavoglurant Total
25 mg 50 mg 100 mg
Total number of patients (N)a 42 31 27 39 139
Number of patients who completed 12 weeks of treatment 40 31 27 37 135
Number of responders (observed number of patients who responded) 8 4 8 8 28
Expected number of respondersb (if distribution of response would have been random) 8.5 6.2 5.4 7.9 28
aOnly data from 134 patients queried for CGI improvement
bUnder the assumption of no treatment effect, i.e., identical response chance for each patient
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treatment duration, and the rater comments are likely to
be based on a higher percentage of objective information
(for example, school grades, standardized testing scores
at school, ability to retain a job, and gaining toilet train-
ing skills) compared with the pure parental report for
narratives in categories such as anxiety, engagement,
and mood.
Furthermore, objective cognitive and functional mea-
sures were not directly assessed as a part of either study;
thus, it is difficult to substantiate or refute the increased
frequency in these areas of reported improvement with
prolonged treatment in the open-label extension. This
observation speaks to the need for novel trial designs in
FXS and neurodevelopmental disabilities in general,
which can evaluate long-term effects of treatments tar-
geting underlying synaptic mechanisms and measuring
disease modification in the form of improved learning
and plasticity. However, these studies would likely re-
quire a time frame that is not amenable to placebo-
controlled trials. Moreover, the need for a long time
frame is likely to be particularly applicable to cohorts of
adolescents and adults, in whom cognitive and func-
tional changes are likely to evolve over more prolonged
periods than for very young children.
Pre-clinically, many studies in FMR1 knockout mice
have shown behavioral and physiological FXS phenotypic
rescue, such as spine morphology, prepulse inhibition,
and audiogenic seizure corrections, following acute
pharmacological inhibition of mGluRs [28–32]. In gen-
eral, these corrections were more effective in younger
animals [30]. Additionally, Michalon et al. demonstrated
more correction of cognitive deficits with chronic versus
short-term treatment with CTEP, a potent long-acting
mGluR5 inhibitor, in young adult mice [33] further indi-
cating the importance of long-term treatment. Although
precise translation from pre-clinical studies into human
trial duration can be debated, the chronic treatment dur-
ation reported (~5 weeks) in the mouse could potentially
correlate to multiple years of treatment in a human.
Thus, it is perhaps not surprising that cognitive gains (if
any) might be relatively modest after only a year of
open-label treatment. This also highlights the need for
natural history models in FXS to determine the effects
of drugs that may act over a very long term for which
placebo-controlled trials are not possible.
Determination of efficacy or improvement through re-
liable, sensitive, standardized, and validated measures
has been a major challenge for clinical trials in patients
with FXS. Typical behavioral phenotype measures in-
clude ABC-C, CGI, SRS, VAS, and RBS, whereas cogni-
tive end point measures include the Repeatable Battery
for the Assessment of Neurological Status and VABS.
Table 3 Distribution of responders in broad improvement categories across the treatment arms (double-blind core study)
Placebo Mavoglurant x2 d.f. p valuea
25 mg 50 mg 100 mg
Anxiety
Number of responders 4 4 4 4 0.13/3.38 1/3 0.72/0.33
Expected number of responders 4.6 2.3 4.6 4.6
Behavior and mood
Number of responders 6 3 5 7 0.13/1.29 1/3 0.72/0.73
Expected number of responders 6 3 6 6
Communication
Number of responders 4 3 5 7 1.95/2.68 1/3 0.16/0.44
Expected number of responders 5.4 2.7 5.4 5.4
Cognitive/academic
Number of responders 3 2 1 5 0.31/4.26 1/3 0.58/0.24
Expected number of responders 3.1 1.6 3.1 3.1
Engagement
Number of responders 6 2 5 8 1.19/4.50 1/3 0.28/0.21
Expected number of responders 6 3 6 6
Functional skills
Number of responders 3 1 1 4 0.08/2.68 1/3 0.77/0.44
Expected number of responders 2.6 1.3 2.6 2.6
Note: Expected number of responders is calculated under the assumption of equal response probabilities across treatments
aCMH test for equal response probabilities across treatments; total number of responders = 28; x2 = chi-squared test statistic; d.f. = degrees of freedom; first x2,
d.f., and p value for trend, second for heterogeneity
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However, there is a general lack of consensus over which
end points are most useful and should be used to assess
the potential treatment effect. This problem was the
subject of a recent meeting arranged by the National In-
stitutes of Health, aiming to identify and standardize
outcome measures for potential use in clinical trials in
patients with FXS. No single measure or set of measures
was identified as optimal, but recommendations were
made as guidelines [16].
The ABC-C is the most widely used assessment in
clinical trials in FXS. It consists of five subscales, irrit-
ability, hyperactivity, lethargy/withdrawal, stereotypy,
and inappropriate speech, associated with a 58-item
checklist [34] and has been adapted for the community
setting [35]. In 2012, Sansone et al. modified the scoring
of the ABC-C for individuals with FXS resulting in
addition of a sixth subscale, social avoidance [17], after
completing a factor analysis on ABC assessments from
approximately 600 subjects pooled from multiple FXS
clinics, a finding subsequently replicated by Wheeler et
al. [36]. Despite the modifications and widespread use of
this scale in the FXS studies, there are certain limitations
that remain. The ABC-C assessment is completed indir-
ectly, by a parent or caregiver, potentially leading to un-
intentional bias and strong placebo effects [16]. Indeed,
during the placebo run-in period of the core double-
blind study, a strong placebo effect was observed in all
treatment groups with substantial improvements in
ABC-CFX total scores.
Therefore, there is a need for more objective outcome
measures. Although the CGI assessment is completed by
a clinician, consideration is given to all available infor-
mation, including caregiver anecdotes. Often the CGI
ratings are predominantly based on the caregiver’s infor-
mation and, as such, are subject to large placebo effects
when there are no systematic objective data to incorporate
into the clinician assessment. Furthermore, the CGI-I re-
ports global changes of symptoms through a seven-point
scale rating, and there are no scoring guidelines or an-
chors. Consequently, the measure may not comprehen-
sively capture all the categories and can also be associated
with variability. Anchors can help guide scoring and re-
duce variability. In addition, the CGI-I may simultan-
eously take into account the improvement in one area and
worsening in another area and hence may hide a very spe-
cific area of response.
Another limitation of this study is the relatively small
number of data points from the core study for analysis
following unblinding with the expected number of re-
sponders in the subcategories being 6 or less per dosing
group (Table 3). In some cases, there was a slight nu-
merical advantage for the 100 mg BID mavoglurant-
treated group, and it is possible that significance could
not be demonstrated due to small sample size. In fact, a
small but important effect size would not be detectable
in this study.
Outcome measures should be sensitive enough to de-
tect improvements over placebo responses and be repro-
ducible and precise, so that they can capture most, if not
all, of the symptom categories. Outcome measures that
are based on direct assessment of the patient to quantify
performance in language, functional, and cognitive cat-
egories are needed so as not to rely entirely on the care-
giver’s reports of behavioral function and change, which
appear to be highly variable in the FXS population and
strongly susceptible to placebo effects.
Conclusions
A method was established to capture symptom categories
in FXS using the CGI-I narratives among patients with
high levels of change during treatment in clinical trials
with mavoglurant. This methodology and the categories
identified could also be useful in future studies for captur-
ing new items and indicating potential scoring anchors.
Analysis of the CGI-I narratives did not indicate a
higher level of treatment response in patients treated with
mavoglurant compared with patients receiving placebo.
However, since many of the comments of specific im-
provements received from the investigators were based on
parental report, this may not represent a completely ob-
jective alternative assessment. In addition, the number of
responders was small, and therefore, the analysis may not
be definitively conclusive about treatment response.
The lack of efficacy observed in the 12-week, double-
blind, placebo-controlled study could be due to lack of effi-
cacy of mavoglurant. However, this analysis does not rule
out the possibility that efficacy could have been evident with
other more robust measures for clinical trials in FXS such
as cognitive or functional measures, as caregiver reported
outcomes can be associated with a high placebo re-
sponse. Future trials may require longer treatment dur-
ation, a younger study population with more plasticity,
outcome measures focusing on improved function, cog-
nition and/or academic achievement, or a modified trial
design to evaluate “neural plasticity” through the in-
corporation of learning interventions, in order to allow
efficacy to manifest.
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